Multivariate analysis of PFS
Variables . | RR of treatment failure (95% CI) . | P . |
|---|---|---|
| Disease type and use of TBI | .002† | |
| NHL with TBI, n = 37 | 1.00 | - |
| NHL no TBI, n = 42 | 2.45 (1.49-4.02) | < .001 |
| HL with TBI, n = 8* | 1.77 (0.78-4.01) | .17 |
| HL no TBI, n = 27 | 1.97 (1.14-3.41) | .01 |
| Disease status before second transplantation | < .001† | |
| Complete remission, n = 24 | 1.00 | - |
| Relapse/primary induction failure, chemosensitive, n = 39 | 1.74 (0.99-3.03) | .06 |
| Relapse/primary induction failure, chemoresistant, n = 23 | 3.91 (2.05-7.44) | < .001 |
| Relapse/primary induction failure, untreated, n = 28 | 3.68 (1.97-6.84) | < .001 |
| Donor type | .05‡ | |
| HLA-identical sibling, n = 70 | 1.00 | - |
| Haploidentical sibling, n = 17 | 1.85 (1.04-3.31) | .04 |
| Unrelated, n = 27 | 1.47 (0.92-2.34) | .11 |
Variables . | RR of treatment failure (95% CI) . | P . |
|---|---|---|
| Disease type and use of TBI | .002† | |
| NHL with TBI, n = 37 | 1.00 | - |
| NHL no TBI, n = 42 | 2.45 (1.49-4.02) | < .001 |
| HL with TBI, n = 8* | 1.77 (0.78-4.01) | .17 |
| HL no TBI, n = 27 | 1.97 (1.14-3.41) | .01 |
| Disease status before second transplantation | < .001† | |
| Complete remission, n = 24 | 1.00 | - |
| Relapse/primary induction failure, chemosensitive, n = 39 | 1.74 (0.99-3.03) | .06 |
| Relapse/primary induction failure, chemoresistant, n = 23 | 3.91 (2.05-7.44) | < .001 |
| Relapse/primary induction failure, untreated, n = 28 | 3.68 (1.97-6.84) | < .001 |
| Donor type | .05‡ | |
| HLA-identical sibling, n = 70 | 1.00 | - |
| Haploidentical sibling, n = 17 | 1.85 (1.04-3.31) | .04 |
| Unrelated, n = 27 | 1.47 (0.92-2.34) | .11 |